Taysha Gene Therapies, Inc.
TSHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.05 | 0.13 | -0.11 |
| FCF Yield | -18.86% | -19.56% | -28.51% | -7.90% |
| EV / EBITDA | -3.43 | -2.62 | -1.99 | -8.35 |
| Quality | ||||
| ROIC | -67.24% | -52.01% | -244.18% | -106.82% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.65 | 0.53 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | 49.34% | – | – | – |
| Free Cash Flow Growth | -1.51% | 29.02% | 18.28% | -248.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.86 | 0.79 | 0.17 | 0.50 |
| Interest Coverage | -896.66 | -14.49 | -42.77 | -121.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -16,145.32 |